Literature DB >> 17097558

Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype.

Mary Lynn Nierodzik1, Simon Karpatkin.   

Abstract

The association of idiopathic venous thrombosis with occult cancer is generally recognized. However, it has not been fully appreciated that thrombin generated during thrombosis can augment the malignant phenotype. Thrombin activates tumor cell adhesion to platelets, endothelial cells, and subendothelial matrix proteins; enhances tumor cell growth; increases tumor cell seeding and spontaneous metastasis; and stimulates tumor cell angiogenesis. These mechanisms are reviewed. Evidence is also presented to support the hypothesis that thrombin serves to preserve dormant tumor cells in individuals, preventing host eradication. It is proposed that tumor malignancy may be regulated by a procoagulant/anticoagulant axis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17097558     DOI: 10.1016/j.ccr.2006.10.002

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  149 in total

Review 1.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

Review 2.  Roles for growth factors in cancer progression.

Authors:  Esther Witsch; Michael Sela; Yosef Yarden
Journal:  Physiology (Bethesda)       Date:  2010-04

3.  Elucidation of flow-mediated tumour cell-induced platelet aggregation using an ultrasound standing wave trap.

Authors:  D Bazou; M J Santos-Martinez; C Medina; M W Radomski
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 4.  PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.

Authors:  Maya Zigler; Takafumi Kamiya; Emily C Brantley; Gabriel J Villares; Menashe Bar-Eli
Journal:  Cancer Res       Date:  2011-10-18       Impact factor: 12.701

5.  Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasis.

Authors:  Eric T Alexander; Allyson R Minton; Candace S Hayes; Ashley Goss; Joanne Van Ryn; Susan K Gilmour
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

6.  Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations.

Authors:  Nathalie Magnus; Delphine Garnier; Brian Meehan; Serge McGraw; Tae Hoon Lee; Maxime Caron; Guillaume Bourque; Chloe Milsom; Nada Jabado; Jacquetta Trasler; Rafal Pawlinski; Nigel Mackman; Janusz Rak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

7.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

Review 8.  The role of platelets in tumour growth.

Authors:  K Pilatova; L Zdrazilova-Dubska; G L Klement
Journal:  Klin Onkol       Date:  2012

9.  G protein-coupled receptors engage the mammalian Hippo pathway through F-actin: F-Actin, assembled in response to Galpha12/13 induced RhoA-GTP, promotes dephosphorylation and activation of the YAP oncogene.

Authors:  Laura Regué; Fan Mou; Joseph Avruch
Journal:  Bioessays       Date:  2013-03-01       Impact factor: 4.345

10.  Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis.

Authors:  Alexander Zaslavsky; Kwan-Hyuck Baek; Ryan C Lynch; Sarah Short; Jenny Grillo; Judah Folkman; Joseph E Italiano; Sandra Ryeom
Journal:  Blood       Date:  2010-01-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.